Brief: Vertex Announces Program Updates For Type 1 Diabetes Portfolio
28/03/2025 20:07
March 28 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES PROGRAM UPDATES FOR TYPE 1 DIABETES PORTFOLIO VX-264 STUDY DID NOT MEET EFFICACY ENDPOINT EXPECTS GLOBAL REGULATORY SUBMISSIONS FOR ZIMISLECEL IN 2026 EFFICACY DATA ARE NOT SUPPORTIVE OF FURTHER CLINICAL ADVANCEMENT OF VX-264 Source text: ID:nBw7mfvZya Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31